European Company Recommends Two Unique Adalimumab Biosimilars
The European Medicines Company’s Committee for Medicinal Merchandise for Human Use instructed marketing and marketing authorization this week for two recent adalimumab biosimilars, Hukyndra and Libmyris. The biosimilars, both developed by STADA Arzneimittel AG, could be available as a 40-mg…